Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: No adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy

Altmann, Paul; Barnett, M. Edwina; Finn, William F.

doi:10.1038/sj.ki.5001932

Cited by 71 publications

(37 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At these doses, up to 6 years of lanthanum carbonate treatment in this long-term follow-up was not associated with any clinically relevant effects on the liver, bone, central nervous system or any other body system. These results are consistent with previous clinical and preclinical studies involving lanthanum [10, 13,16,17,18,19,20,21,22,23,24]. …”

Section: Discussionsupporting

confidence: 82%

Long-Term Efficacy and Safety Profile of Lanthanum Carbonate: Results for up to 6 Years of Treatment

Hutchison

Barnett²,

Krause³

et al. 2008

Nephron Clin Pract

104

View full text Add to dashboard Cite

Background/Aims: Lanthanum carbonate (LC, FOSRENOL®) is an effective phosphate binder for which tolerability and a safety profile have been reported in haemodialysis patients. Patients from previous studies entered a 2-year extension, enabling assessment of efficacy and safety for up to 6 years of LC monotherapy. Methods: Patients from four previous trials entered this study. Results: Ninety-three patients started the extension, with 22 entering a sixth year of LC treatment. Two-thirds of all patients received LC doses of 2,250 or 3,000 mg/day. Reductions in serum phosphate and calcium × phosphate product were maintained for up to 6 years. There were no new or unexpected adverse events (AEs), and no increase in the incidence of events with increasing treatment exposure. Over the complete duration of therapy, treatment-related AEs occurred in 25.8% of patients and were primarily gastrointestinal in nature. No clinically relevant changes in liver function tests were observed and there was no evidence of adverse effects on the liver, bone or the central nervous system. Conclusions: LC monotherapy was effective and well tolerated for up to 6 years with no evidence of safety concerns or increased frequency of AEs.

show abstract

Section: Discussionsupporting

confidence: 82%

Long-Term Efficacy and Safety Profile of Lanthanum Carbonate: Results for up to 6 Years of Treatment

Hutchison

Barnett²,

Krause³

et al. 2008

Nephron Clin Pract

104

View full text Add to dashboard Cite

show abstract

“…In this long-term follow-up study, lanthanum carbonate was not associated with organ-specific toxicity in liver or bone. In addition, a detailed assessment over 2 yr showed no difference in changes in cognitive function between patients receiving lanthanum carbonate or alternative phosphate binders (30), providing clinical confirmation of animal experiments demonstrating that lanthanum does not cross the blood-brain barrier (31).…”

Section: Discussionmentioning

confidence: 92%

Lanthanum Carbonate Reduces Phosphorus Burden in Patients with CKD Stages 3 and 4

Sprague¹,

Abboud²,

Qiu³

et al. 2009

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…Lanthanum was reported to have no effect on decline in cognitive function versus standard phosphate binder therapy in dialysis patients over 2 years; however, a substantially higher dropout and shorter follow-up in the lanthanum group versus standard treatment group may limit the conclusions of this study [84]. …”

Section: Safety Data Tolerability and Concerns Around Current Phospmentioning

confidence: 62%

Non-Calcium-Containing Phosphate Binders: Comparing Efficacy, Safety, and Other Clinical Effects

Frazão

Adragão

2012

Nephron Clin Pract

View full text Add to dashboard Cite

Phosphate-binder therapy for hyperphosphataemia is key to the treatment of patients with chronic kidney disease (CKD)-mineral and bone disorder (MBD). Calcium-free phosphate binders are increasingly favoured since calcium-based agents potentially cause harmful calcium overload and vascular calcification that confound the benefits of reducing serum phosphorus. Several calcium-free phosphate binders are available, including the non-absorbed agent sevelamer and the absorbed agents, e.g. lanthanum and magnesium salts. Randomised controlled studies consistently show that sevelamer and lanthanum carbonate offer equivalent lowering of serum phosphorus and often effectively achieve phosphorus targets versus calcium salts, with sevelamer having a positive effect on bone disease, vascular calcification, and patient-level outcomes in dialysis patients in several trials. There is also evidence that lanthanum carbonate can improve bone health, but data are limited to its effects to vascular calcification or patient-level outcomes. Magnesium salts have also been shown to reduce serum phosphorus levels, but clear evidence is lacking on bone, vascular, or clinical outcomes. It also remains to be established whether long-term systemic accumulation of lanthanum and magnesium, in tissues including bone, has clinically relevant toxic effects. This review summarises the evidence of efficacy and safety for newer calcium-free phosphate binders in CKD-MBD management.

show abstract

Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: No adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy

Cited by 71 publications

References 36 publications

Long-Term Efficacy and Safety Profile of Lanthanum Carbonate: Results for up to 6 Years of Treatment

Long-Term Efficacy and Safety Profile of Lanthanum Carbonate: Results for up to 6 Years of Treatment

Lanthanum Carbonate Reduces Phosphorus Burden in Patients with CKD Stages 3 and 4

Non-Calcium-Containing Phosphate Binders: Comparing Efficacy, Safety, and Other Clinical Effects

Contact Info

Product

Resources

About